Pfizer (PFE) Misses Q4 EPS by 3c; Issues Lackluster Guidance

Pfizer (NYSE: PFE) reported Q4 EPS of $0.47, $0.03 worse than the analyst estimate of $0.50. Revenue for the quarter came in at $13.6 billion versus the consensus estimate of $13.64 billion.

GUIDANCE:

Pfizer sees FY2017 EPS of $2.50-$2.60, versus the consensus of $2.57. Pfizer sees FY2017 revenue of $52-54 billion, versus the consensus of $54 billion.

For earnings history and earnings-related data on Pfizer (PFE) click here.

You May Also Be Interested In

• Pfizer's Litfulo meets Phase 3 endpoints for vitiligo treatment
• Tesla (TSLA) Delivered 486,532 Vehicles in Q3 vs Consensus of 461,974
• ConAgra Brands (CAG) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY27 EPS Guidance